Short answer
Medpace Holdings Inc (MEDP) filed an 8-K current report with the SEC on October 21, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026.
Medpace Holdings Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026
- Press release available as Exhibit 99.1, containing the detailed operating and financial figures
Item 8.01 · Other Events
- Prior authorization terminated October 20, 2026, with $527.0 million unused
- New $1.0 billion repurchase authorization runs through December 31, 2028
- Cash-funded buybacks signal capital-return flexibility, potentially reducing shares outstanding
- Repurchases discretionary, dependent on market conditions and alternative capital uses
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $716.0M, up 8.5%, with net new awards $873.4M, up 10.6%, supporting continued demand
- Backlog $3.167B, up 5.6%, but 23.8% conversion rate highlights reliance on execution and timing
- GAAP EPS $4.84 versus $3.86, with net margin expanding to 19.2% from 16.8%
- Cash $705.3M and operating cash flow $530.4M year to date, providing substantial capital-return capacity
- New $1.0B repurchase authorization through December 31, 2028, replacing the prior $527.0M authorization-remainder program
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Medpace Holdings Inc 8-K filings
Get the next MEDP 8-K as it lands
Follow MEDP for push alerts, or ask the research agent what this filing means.